Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease? | Citedby Results | Digestive Diseases | Karger Publishers

Skip to Main Content

Skip Nav Destination

Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?

Dig Dis (2017) 35 (1-2): 74–82.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Use of Biosimilars in Pediatric Inflammatory Bowel Disease

Lissy de Ridder
Amit Assa
Jiri Bronsky
Claudio Romano
Richard K. Russell
Nadeem A. Afzal
Almuthe C. Hauer
Daniela Knafelz
Paolo Lionetti
Caterina Strisciuglio
Gábor Veres
Harland Winter
Victorien M. Wolters
Malgorzata Sladek
Arnold G. Vulto
Jorge A. Dias

Journal of Pediatric Gastroenterology and Nutrition (2019) 68 (1): 144.

Characteristics of biological therapy in pediatric patients with Crohn’s disease

Andras Tarnok
Zoltan Kiss
Orsolya Kadenczki
Gabor Veres

Expert Opinion on Biological Therapy (2019) 19 (3): 181.

Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population

Marte L. Høivik
Lydia C. T. Buer
Milada Cvancarova
David J. Warren
Nils Bolstad
Bjørn A. Moum
Asle W. Medhus

Scandinavian Journal of Gastroenterology (2018) 53 (6): 692.

Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study

Lydia C. T. Buer
Bjørn A. Moum
Milada Cvancarova
David J. Warren
Asle W. Medhus
Marte Lie Høivik

Journal of Crohn's and Colitis jjw166.